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WIN-55,212-2 (WIN-2) can elicit anti-inﬂammatory and cognitive-enhancing effect in aged rats. The current
study was designed to determine the differential role of the endocannabinoid receptor sub-types 1 (CB1) and
2 (CB2) and transient receptor potential vanilloid 1 receptor (TRPV1) in the reduction of age-associated brain
inﬂammation and their effects on neurogenesis in the dentate gyrus of aged rats. Our results demonstrate
that 1) the antagonist actions of WIN-2 at the TRPV1 receptor are responsible for the reduction in microglial
activation and 2) the agonist actions of WIN-2 at CB1/2 receptors can trigger neurogenesis in the
hippocampus of aged rats. Chronic treatment with WIN-2 established an anti-inﬂammatory cytokine proﬁle
within the hippocampus. Our results provide insight into the role of the endocannabinoid and vanilloid
systems upon two different and detrimental aspects of normal and pathological aging, chronic
neuroinﬂammation and decline in neurogenesis.
© 2009 Elsevier Inc. All rights reserved.
Introduction
Inﬂammatory changes are closely related to the clinical manifesta-
tionsofmanyage-relateddiseasesofthebrain(Akiyamaetal.,2000).A
central element of the brain's inﬂammatory response during neuro-
degenerative diseases is activated microglial cells (Akiyama et al.,
2000; Hauss-Wegrzyniak et al., 1998; Streit, 2004). Clinical beneﬁts
might be achieved by adjusting the microglial response to one which
will beneﬁt recovery and protect neurons from further damage rather
than contributing tothe degeneration (Prince et al.,1998; Blasko et al.,
2004, 2007). Recent studies suggest that drugs targeting the
endocannabinoidsystemmayproveusefulinthetreatmentofdiseases
associated with neuroinﬂammation, including multiple sclerosis,
Parkinson's disease (PD) and Alzheimer's disease (AD, Maresz et al.,
2005; Ramirez et al., 2005; Eljaschewitsch et al., 2006; Marchalant
et al., 2007, 2008a, 2008b). The current challenge is to avoid targeting
the components of this neurotransmitter system that are responsible
for its psychoactive proclivities. The endocannabinoid system in the
brain is composed of two major molecules derived from arachidonic
acid, arachidonoylethanolamide or anandamide and 2-arachidonoyl
glycerol or 2-AG, that bind primarily to endocannabinoid receptors
type 1 (CB1) and type 2 (CB2) along with the transient receptor
potential vanilloid type 1 receptor (TRPV1). We have previously
demonstrated the anti-inﬂammatory effect of a low dose of WIN-
55,212-2 (WIN-2) in young rats chronically infused with lipopolysac-
charide intothe 4th ventricle (I.C.V) and normal aged rats (Marchalant
et al., 2007, 2008a). However, it is not known whether the anti-
inﬂammatory effect of WIN-2 was achieved through the CB1, CB2 or
TRPV1 receptors because WIN-2 is an agonist at the CB1 and CB2 and
an antagonist at the TRPV1. Moreover, the relation between neuroin-
ﬂammation and neurogenesis during normal and pathological aging
also remains unclear (Ekdahl et al., 2008, for review). Neurogenesis
occurs in the dentate gyrus (DG) via the mitosis of neural progenitor
cells located in the subgranular zone (SGZ) (Gage et al., 1998; Kokaia
and Lindvall, 2003; Lledo et al., 2006) and may play an important role
in the maintenance of hippocampal functions such as learning and
memory(VanPraagetal.,2000;Shorsetal.,2001;Aimoneetal.,2006).
NeurogenesisintheDGdeclinesdramaticallyduringnormalagingand
this decline may underlie many aspects of cognitive deﬁcits of
dementia associated with Alzheimer's disease (Galvan and Bredesen,
2007 for review; Chen et al., 2008). Recent studies suggest that the
endocannabinoid system may control the proliferation of newly
generated neurons via either CB1 receptors (Aguado et al., 2005,
2007) or CB2 receptors (Goncalves et al., 2008). The current study
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the reduction of age-associated brain inﬂammation and in the control
of neurogenesis in the DG of the aging hippocampus. This information
may lead to more effective and selective manipulation of the
endocannabinoid system in the aging brain.
Experimental procedures
Subjects and surgical procedures
Fifty four aged (23 months old) male F-344 rats (Harlan Sprague–
Dawley, Indianapolis, IN) were singly housed in Plexiglas cages with
free access to food and water were maintained on a 12/12 h light–dark
cycle in a temperature-controlled room (22 °C) with lights off at 0900.
All rats were given health checks, handled upon arrival and allowed at
least one week to adapt to their new environment prior to surgery.
WIN-2 (2 mg/kg/day, Sigma, St-Louis, MO), Rimonabant, a selective
CB1 antagonist (SR141716 or SR1, Sanoﬁ-Aventis, Montpellier, France,
3 mg/kg/day), SR144528, a selective CB2 antagonist (SR2, Sanoﬁ-
Aventis, Montpellier, France, 1 mg/kg/day) or the vehicle (dimethyl-
sulfoxide/Polyethylene glycol (50/50v) DMSO/PEG Sigma, St-Louis,
MO) were chronically infused for 21 days subcutaneously (s.c.) using
an osmotic minipump (Alzet, Cupertino, CA, model 2ML4, to deliver
2.5 μl/h) implanted into the dorsal abdomen area. The selective TRPV1
antagonist, 5′-I-RTX (5′-Iodoresiniferatoxin, Tocris, MO, 1 μg/kg/day)
was chronically infused via an indwelling cannula into the 4th
ventricle for 21 days using an osmotic minipump (Alzet, Cupertino,
CA, model 2004, to deliver 0.25 μl/h) according to a previously
described surgical implantation approach (Hauss-Wegrzyniak et al.,
1998). The doses of SR1, SR2 and 5′-I-RTX were previously demon-
strated to effectively antagonize CB1, CB2 and TRPV1 receptors,
respectively (Rinaldi-Carmona et al., 1995, 1998; Jhaveri et al., 2005).
Rats were assigned to one of the six following groups: vehicle
(n=11), WIN (n=9), WIN+SR1 (n=9), WIN+SR2 (n=10), WIN+SR1/
SR2 (n=8), and 5′-I-RTX (n=7).
Histological procedures
After three weeks of drug treatment each rat was deeply
anesthetized with isoﬂurane and prepared for a transcardial perfusion
of the brainwith coldsalinecontaining1 U/ml heparin,followed by4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. The brains were
post-ﬁxed overnight in the same ﬁxative and then stored (4 °C) in
phosphate buffered saline (PBS), pH 7.4. Free-ﬂoating coronal sections
(40 μm) were obtained using a vibratome for staining with standard
avidin/biotin peroxidase or ﬂuorescence labeling methods.
Single immunocytochemistry
The monoclonal antibody OX-6 (ﬁnal dilution 1:400, Pharmigen,
San Diego, CA) was used to visualize activated microglia cells. This
antibody is directed against Class II major histocompatibility complex
(MHC II) antigen. The polyclonal antibody anti-capsaicin receptor
(TRPV1, ﬁnal dilution 1:250, Chemicon, Temecula, CA) was used to
visualize TRPV1 receptors. The antibody doublecortin (DCX, ﬁnal
dilution 1:250, Santa Cruz, CA) was used to visualize progenitors and
immature granule cells. All procedures were conducted as previously
described (Rosi et al., 2005). Brieﬂy, after quenching endogenous
peroxidase activity and blocking nonspeciﬁc binding, the sections
were incubated (4 °C) overnight (or 48 h for DCX) with the primary
antibody. Thereafter, the sections were incubated for 2 h (22 °C) with
the secondary monoclonal antibody, rat adsorbed biotinylated horse
anti-mouse immunoglobulin G (ﬁnal dilution 1:200, Vector, Burlin-
game, CA) for OX-6, rat adsorbed biotinylated horse anti-rabbit
Immunoglobulin G (ﬁnal dilution 1:150, Vector, Burlingame, CA) for
TRPV1 and rat adsorbed biotinylated horse anti-goat immunoglobulin
G( ﬁnal dilution 1:200, Vector, Burlingame, CA) for DCX. Sections were
then incubated for 1 h (22 °C) with avidin-biotinylated horseradish
peroxydase (Vectastain, Elite ABC kit, Vector, Burlingame, CA). After
washing again in PBS, the sections were incubated with 0.05% 3, 3′-
diaminobenzidine tetrahydrochloride (Vector, Burlingame, CA) as
chromogen. The reaction was stopped by washing the sections with
PBS. No staining was detected in the absence of the primary or
secondary antibodies. Sections were mounted on slides, air-dried and
coverslipped with cytoseal (Allan Scientiﬁc, Kalamazoo, MI) mounting
medium. The location of immunohistochemically-deﬁned cells was
examined by light microscopy. Quantiﬁcation of cell density in the
reconstructed hippocampal coronal sections was assessed with
MetaMorph imaging software (Universal Image Corporation, West
Chester, PA). To quantify the activated microglia, the hippocampal
coronal sections were analyzed with Meta-Morph imaging software
(Universal Imaging Corporation, West Chester, PA). The hippocampus
was divided into three areas of interest (CA1, CA3, and the DG). After
drawing these regions in each reconstructed image, a threshold tool
was used to detect all of the OX-6 staining, and the area of each object
was measured. All images were analyzed using the same threshold
settings. The detected objects ranged from 5 to 2000 mm
2. After
creating a distribution curve, only those objects of sizes N65 mm
2
were included in the analysis (the average size was 100 mm
2). This
object size was chosen to match more accurately the size of activated
microglial cells andthereforesigniﬁcantly reduce samplingerrors. The
resulting number of objects was then corrected using the total area of
each region of interest, and the number of objects per region (in
millimeter square) was reported.
Double immunoﬂuorescence staining
Free ﬂoating sections were mounted on slides and air-dried. The
tissues were thenprocessed as described previously (Rosi et al., 2005).
Brieﬂy, after washing in TBS solution the polyclonal antibody anti-
capsaicin receptor (TRPV1, ﬁnal dilution 1:250, Chemicon, Temecula,
CA) was applied. After 24 h of incubation at 4 °C, the sections were
incubated for 2 h at room temperature with the secondary anti-rabbit
biotinylatedantibody(Vector,Burlingame,CA),followedbyincubation
with avidin+biotin ampliﬁcation system (Vector, Burlingame, CA) for
45 min. The staining was visualized using the TSAﬂuorescence system
CY3 (PerkinElmer Life Sciences, Emeryville, CA). After washing in TBS
solution, the tissues were quenched and blocked again and incubated
with either of the following: a monoclonal antibody to MHC-II (OX-6,
Pharmigen, San Diego, CA, ﬁnal dilution 1:400), the monoclonal
antibodyanti-GFAP(Chemicon,Temecula,CA,ﬁnaldilution1:500),the
monoclonal antibody anti-neuronal nuclei (Chemicon, Temecula, CA,
ﬁnal dilution 1:500), or the monoclonal antibody OX-42 (BD
Pharmingen, San Jose, CA ﬁnal dilution 1:400) for 24 h (4°C). Before
applying the biotinylated monoclonal secondary rat absorbed anti-
body (Vector, Burlingame, CA) for 2 h, the tissue was incubated with
Avidin Biotin Blocking Kit (Vector, Burlingame, CA) for 30 min to block
cross reaction with the primary staining. Following treatment with an
avidin+biotin ampliﬁcation system (Vector, Burlingame, CA), the
staining was visualized with a TSA ﬂuorescence system CY5 (Perki-
nElmer Life Sciences, Emeryville, CA) and the nuclei were counter-
stained with Sytox-Green (Molecular Probes, Eugene, OR). No staining
was detected in the absence of the primary or secondary antibodies.
RT-PCR
Samples of hippocampus were microdissected and total RNA was
extracted by homogenization (Ultra-Turrax T8, IKA Works, Wilming-
ton, NC) using an RNeasy Mini Kit (Qiagen, Valencia CA) according to
manufacturer's protocol. Extracted RNA was suspended in 30 μLo f
RNase-free water and RNA concentration was determined by a
s p e c t r o p h o t o m e t e r( N a n o D r o pN D - 1 0 0 0 ,W i l m i n g t o n ,D E ) .T h e
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City, CA) were used: IL-1 beta (Assay ID: Rn00580432_m1), TNF-alpha
(Assay ID: Rn99999017_m1), IL-1RA (Rn00573488_m1), IL-6 (Assay
ID: Rn01410330_m1). A TaqMan 18S rRNA primer and probe set
(labeled with VIC dye: Applied Biosystems, Foster City, CA) were used
as a control gene for relative quantiﬁcation. Ampliﬁcation was
performed on an ABI 7000 Sequencing Detection System by using
Taqman Universal PCR master mix. The universal two-step RT-PCR
cycling conditions used were: 50 °C for 2 min, 95 °C for 10 min
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
ELISA
Samples of hippocampus were microdissected, weighed and
homogenized in buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 1.0%
Triton X-100, and 0.5% sodium deoxycholate) containing protease
inhibitors (Bennett et al., 2003). Homogenates were centrifuged
(12,000 rpm) for 20 min at 4°C; the resuspended pellets were
centrifuged (12,000 rpm) for 20 min at 4 °C to obtain total cell lysates.
Protein concentrations were determined using bovine serum albumin
as a standard (Bradford, 1976). Tissue homogenates were stored
(−80 °C) until assayed in duplicate using sandwich enzyme-linked
immunosorbent assay kits for IL-RA(R&D Systems, Minneapolis, MN),
TNF-α, IL-6 and IL-1β (Biosource, Carlsbad, California) according to
the manufacturer's guidelines. Optical density of each plate was read
(450 nm ﬁlter on a Bio-Rad Benchmark microplate reader, Richmond,
CA) and the mean optical density of each sample was calculated.
Statistical analysis
All statistical analyses were performed using Statview software
(SAS Institute Inc., NC). Results are expressed as means±SD. Statistical
Fig.1. (A) Activated microglia in the CA3 region. Note the diminution of activated microglia cells in this region of rats treated with 2 mg/kg/day of WIN-55,212-2 (b), as compared to
the normal aged rats (a). None of the CB1/2 receptor antagonists, alone or in combination, could reverse the anti-inﬂammatory effect induce by WIN-2 (c–e). Magniﬁcation 160×. (B)
Density of activated microglial cells in different areas of interest. The infusion of 2 mg/kg/day of WIN-55,212-2 partially reversed the aged induction of activated microglia (⁎pb0.05)
in the dentate gyrus and CA3 region. None of the drugs' combination of CB1 and/or CB2 antagonist used to counteract the anti-inﬂammatory of WIN-55,212-2 had any signiﬁcant
effect.
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was found (pb0.05) a post hoc analysis was made using the Fisher's
PLSD test. A p-value lower than 5% was considered signiﬁcant for each
analysis.
Results
Chronic infusion of all drugs and vehicle were well tolerated by all
rats and all rats gained weight normally during the treatment
regimen.
Histology
Immunostaining (Fig. 1A) revealed activated microglia (OX-6-
immunopositive) cells distributed throughout the hippocampus of old
rats (Fig. 1A-a). The activated microglia had a characteristic bushy
morphologywithincreased cell bodysize and contracted andramiﬁed
processes consistent with our previous study (Marchalant et al.,
2008a). WIN-2 reduced the number of immunostained microglia
within the hippocampus of old rats when administered alone (Fig.1A-
b) or in combination with SR1, SR2, SR1+SR2 (Fig. 1A-c,d,e).
Regional microglia cell counts
The number of OX-6-immunoreactive (OX6-IR) microglia per
millimeter square was determined in 3 different areas of interest:
DG, CA3 and CA1 regions of the hippocampus (Fig. 1B). These brain
regions were examined because of their importance for spatial
learning (Nadel and Land, 2000). An ANOVA revealed an overall effect
of the treatments on the number of OX-6-immunoreactive microglia
in the DG (F8, 36=5.053, p=0.0003), in the CA3 (F8, 36=5.424,
p=0.0002) but not in the CA1 region (F8, 36=1.375, p=0.2403). In the
DG, and in the CA3 region, all treatments reduced signiﬁcantly the
number of OX-6-IR cells compare to vehicle treated rats (⁎pb0.05,
Fisher's PLSD post-hoc test).
Effect of WIN-2 on neurogenesis
Although very few doublecortin-IR (DCX-IR) cells were detected in
the DG of aged animals infused with the vehicle, WIN-2 treatment
Fig. 2. (A) Double cortin immunoreactive (DCX-IR) cells in the dentate gyrus region.
Note the increase in DCX-IR cells in this region of rats treated with 2 mg/kg/day of WIN-
55,212-2 (b), as compared to the normal aged rats (a). Magniﬁcation 160×. (B) Average
number of DCX-IR cells in the dentate gyrus. The infusion of 2 mg/kg/day of WIN-
55,212-2 increased signiﬁcantly the number of DCX-IR cells (⁎pb0.05) in the dentate
gyrus. All drugs' combination of CB1 and/or CB2 antagonist did signiﬁcantly blocked the
increase in DCX-IR induced by WIN-55,212-2 (
†pb0.05).
Fig. 3. Cytokine expression proﬁle following 4 weeks of treatment with WIN-55,212-2.
(A)ChangesinmRNAcytokineexpressioninthehippocampus ofoldratstreatedwithor
without WIN-55,212-2. Hippocampal level of IL1-RA and IL-6 mRNA expression were
signiﬁcantlydifferentafterthe4weektreatment(⁎pb0.05)comparedtooldcontrolrats.
(B) Changes in cytokine protein level in the hippocampus of old rats treated with or
without WIN-55,212-2. Hippocampal protein level of IL1-RA, TNF-α and IL1-β were
signiﬁcantlydifferentafterthe4weektreatment(⁎pb0.05)comparedtooldcontrolrats.
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number of DCX-IR cells per DG was determined (Fig. 2B). An ANOVA
revealed an overall effect of treatment on the number of DCX-IR cells
in the dentate gyrus (F4, 256=5.545, p=0.0008). WIN-2 signiﬁcantly
increased DCX-IR compare to vehicle treated rats (⁎pb0.05, Fisher's
PLSD post-hoc test). All combinations of WIN-2 with CB1 and/or CB2
antagonist returned DCX-IR cells to vehicle infused level (
†pb0.05,
Fisher's PLSD post-hoc test).
Effect of 4 weeks infusion of WIN-2 upon cytokine expression proﬁle
After 4 weeks of subcutaneous (s.c.) administration of WIN-2, the
mRNA level of 4 cytokines, one anti-inﬂammatory (IL1-RA) and 3 pro-
inﬂammatory (TNFα,I L - 1 β,I L - 6 ), were measured within the hippo-
campus (Fig. 3A; expressed as a ratio between mRNA and control
gene's mRNA). No signiﬁcant difference were found between vehicle
treated and WIN-2 infused animals for TNF-α (F1,8=0.016, p=0.903) or
IL-1β (F1,8=0.146, p=0.712). However, a signiﬁcant decrease was
found after WIN-2 treatment for IL-6 (F1,8=7.475, p=0.026) while a
signiﬁcant increase was observed for IL1-RA (F1,8=15.056, p=0.0047).
The protein level of those cytokines was also determined by ELISA
(Fig. 3B). No signiﬁcant difference was found between vehicle treated
and WIN-2 animals for IL-6 (F1,6=5.603, p=0.056). However, WIN-2
treatment produced a signiﬁcant decrease in TNF-α (F1,6=24.67,
p=0.025) and IL-1β (F1,6=6.372, p=0.045) while a signiﬁcant increase
was observed for IL1-RA (F1,6=6.1 71 ,p=0.0475) in the hippocampus.
Effects of the TRPV1 antagonist 5′I-RTX on neuroinﬂammation and
neurogenesis
The selective TRPV1 antagonist 5′I-RTX reduced the number of OX-
6-immunoreactive microglia cells within the CA3 region of the
hippocampus as compared to vehicle-treated rats (Fig. 4A,
F2,12=8.547, p=0.0049). Treatment with 5′I-RTX did not inﬂuence
the number of DCX-IR cells (Fig. 4B). Indeed, no signiﬁcant difference
was found between vehicle and 5′I-RTX treated rats (ANOVA,
†pb0.05,
Fisher's PLSD post-hoc test) while a signiﬁcant difference was
observed between WIN-2 and vehicle treated rats and between
WIN-2 and 5′I-RTX treated rats (ANOVA, ⁎pb0.05, Fisher's PLSD post-
hoc test).
Co-localization between TRPV1 and other cell types in the hippocampus
As previously described by others using the same antibody (Tóth
et al., 2005), a strong TRPV1 immunoreactivity was observed in the
hippocampus (Fig. 5A) and the cortex, mostly within the soma of
neurons. The staining was punctate, non-homogenous and not
restricted to the plasma membrane.
Double-immunoﬂuorescence staining for TRPV1 receptors and
neurons (NeuN) demonstrated a strong spatial co-localization
between TRPV1-IR and the soma of neurons in the hippocampus
across all groups (Fig. 5Ba–c). These results are consistent with studies
showing that TRPV1 receptors are closely associated with neurons in
the regions of interest; DG, CA1 and the CA3 region of the
hippocampus (Tóth et al., 2005).
Double-immunoﬂuorescence staining for TRPV1 receptors and
astrocytes (GFAP-IR, Fig. 5Bd–f), activated microglia (OX-6-IR,
Fig. 5Bg–i) and total microglia (OX-42, Fig. 5Bj –l) did not demonstrate
any co-localization between these biomarkers. These results suggest
that TRPV1 are not present on astrocytes or on microglial cells in aged
rats or in response to WIN-2 treatment.
Discussion
Our results demonstrate for the ﬁrst time that i) antagonism of
TRPV1 in the brain reduces chronic microglia activation in an aged
brain; ii) CB1 and CB2 agonism can reverse the effect of aging on the
production of new neurons in the hippocampus and that iii) both CB1
and CB2 are required to produce this neurogenic effect.
The current study is the ﬁrst to demonstrate that the speciﬁc
components of the endocannabinoid system can be differentially
targeted to counteract two detrimental aspects of normal aging,
chronic neuroinﬂammationand the decline in neurogenesis, that have
been implicated in age- or disease-related decline in cognitive
function (Akiyama et al., 2000; Greenberg and Jin, 2006).
TRPV1 receptors and neuroinﬂammation
Impaired spatial memory in rats parallels the age-associated
appearance of inﬂammation within the hippocampus (Hauss-Wegr-
zyniak et al., 1999; Gemma and Bickford, 2007). The ability of WIN-2
Fig. 4. Effect of 5′-Iodo-resiniferatoxin on inﬂammation and neurogenesis in the hippocampus of old rats. (A). Density of activated microglial cells in different areas of interest. The
infusion of 1 μg/kg/day I.C.V of 5′-I-RTX for 4 weeks reproduced the reduction of the number of activated microglia observed following 2 mg/kg/day of WIN-55,212-2 in the CA3
regionof the hippocampus (⁎pb0.05). (B) Averagenumber of DCX-IR cells in the dentategyrus. The infusion of 0.4 μg/day I.C.V of 5′-I-RTX for 4 weeks did notreproducethe increased
number of DCX-IR cells observed following 2 mg/kg/day of WIN-55,212-2 in the dentate gyrus region of the hippocampus (
#pb0.05).
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unique and encouraging as microglia in those animals are unrespon-
sive to long term therapy with non-steroidal anti-inﬂammatory drugs
(Rozovsky et al., 1998; Hauss-Wegrzyniak et al., 1999). In contrast,
treatment with WIN-2 signiﬁcantly decreased microglial activation in
the CA3 and DG. Our results indicate that antagonism of the TRPV1
receptor is sufﬁcient to reduce microglial activation in the CA3 region
of the hippocampus in aged rats and highlights anotherimportantrole
for the TRPV1 receptor in addition to its known involvement in pain
modulation (Cui et al., 2006) and hippocampal LTD (Gibson et al.,
2008). One potential mechanistic explanation for why the decrease in
microglial activation within the CA1 and DG following treatment with
5′I-RTX did not reach statistical signiﬁcance is that these two regions
exhibit fewer microglia than the CA3, and therefore might be less
susceptible to the actions of WIN-2, i.e. there was a ﬂoor-effect.
Chronic neuroinﬂammation in the hippocampus is associated
with increased levels of endogenous glutamate and increased entry
of calcium ions via NMDA glutamate receptors and the inappropriate
activation of calcium-dependent enzymes, proteins and genes (Bezzi
et al., 1998; Rosi et al., 2005, 2006; Wenk et al., 2006). Treatment
with the NMDA channel antagonist memantine restores normal
calcium homeostasis, reduces over-expression of speciﬁc genes and
proteins and restores normal performance in the water maze task in
young inﬂamed rats (Rosi et al., 2005, 2006). In the current study,
Fig. 5. Immunoreactivity (IR) of TRPV1 inthe CA3regionof the hippocampus. All magniﬁcation 800×.(a–c)NeuN-IR(green)and TRPV1-IR (red)do co-localize inthe CA3 regionof the
hippocampus. (d–f), GFAP-IR (green) and TRPV1-IR (red) do not co-localize in the CA3 region of the hippocampus. (g–i) OX-6-IR (green) and TRPV1-IR (red) do not co-localize in the
CA3 region of the hippocampus. (j–l) OX-42-IR (green) and TRPV1-IR (red) do not co-localize in the CA3 region of the hippocampus. TRPV1-IR thus seems to be located primarily
within neurons in the hippocampus. These photomicrographs are representative of the staining observed in all groups.
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receptor, however, TRPV1 receptors in the hippocampus were
primarily localized on neurons, thereby suggesting an indirect
modulation of glial cells via post-synaptic TRPV1 receptor modula-
tion. Blockade of TRPV1 receptors by 5′I-RTX can reduce the entry of
calcium ions into neurons (Van der Stelt et al., 2005). The reduced
activation of microglia in the current study may be due to the ability
of WIN-2 to antagonize TRPV1 receptors and thereby reduce the
inﬂux of calcium ions into neurons and restore the subsequent
neuron-glia communication to an anti-inﬂammatory state in a
manner similar to that previously described (Rosi et al., 2006). We
hypothesize that a major underlying problem in the development of
age-associated neurodegenerative disorders is a failure of the glia to
respond appropriately to neuronal signaling; therefore, the glia fail to
convert from a pro-inﬂammatory activation state to an anti-
inﬂammatory activation state, leading to excessive calcium entry
and neuronal injury.
Chronic WIN-2 activity on cytokine mRNA and protein expression
A pro-inﬂammatory environment characterized by elevated levels
of cytokines and activated microglia is associated with many age-
related diseases of the brain, including AD, multiple sclerosis and PD
(Akiyama et al, 2000; Wenk and Hauss-Wegrzyniak, 2003). Ther-
apeutic approaches using standard anti-inﬂammatory drugs have not
produced clinical beneﬁts in patients with AD (ADAPT, 2007; Kang
et al., 2007) in contrast to the ﬁndings of numerous epidemiological
studies of people using non-steroidal anti-inﬂammatory drugs that
suggest that long term use of these drugs can slow the onset of AD
symptoms (Rozzini et al.,1996; Prince et al.,1998). We havepreviously
shown that microglia in the brains of aged rats are unresponsive to
long term therapy with non-steroidal anti-inﬂammatory drugs
(Rozovsky et al., 1998; Hauss-Wegrzyniak et al., 1999). Therefore, the
timing of the anti-inﬂammatory drug therapy is critical because
microglia may become progressively unresponsive to standard
therapeutic interventions, such as cyclooxygenase inhibitors or
steroids, with normal aging. In the current study, the anti-inﬂamma-
tory proﬁle, i.e. a down-regulation of pro-inﬂammatory cytokines
(TNFα,I L - 1 β, IL-6) and up-regulation of an anti-inﬂammatory
cytokine (IL1-RA), observed following 4 weeks infusion of WIN-2 is
of great interest because it demonstrates that long term manipulation
of the endogenous cannabinoid and vanilloid systems can alter the
proﬁle of pro- and anti-inﬂammatory cytokines leading to a reduced
level of neuroinﬂammation. Further experiments are needed to
determine whether selective TRPV1 antagonists alone are capable of
sustained anti-inﬂammatory effects in the aged brain.
CB receptors and neurogenesis
Neurogenesis is thought to be involved in normal hippocampal
function as well as in brain repair following injury (Verret et al., 2007
for review). Newly generated cells are produced in the subgranular
zone of the DG and the subventricular zone along the lateral ventricle
in the forebrain. A growing interest in the fate of these cells during
normal aging and neurodegenerative disease has generated in ﬁnding
novel ways to stimulate neurogenesis in order to treat various
neurological disorders (Greenberg and Jin, 2006). Results from our
lab (unpublished) and others (Hwang et al., 2007, 2008) using DCX as
a marker of neuronal progenitors indicates that aging is associated
with a decrease in newlygenerated neurons in various species of aged
animals. Other methods of detection of newly generated cells exist,
notably retroviral incorporation and bromo-deoxyuridine (BrdU), but
they may present a drawback when studying aging and brain
inﬂammation: the intracranial injection necessary to perform retro-
viral incorporation can trigger lesions as well as inﬂammation
(Yamada et al., 2004). Although BrdU is commonly used in young
animals this approach may exhibit altered entry properties in the
brain during aging (Cameron and Mckay, 2001).
Our current study indicates that the stimulation of both subtypes
of CB receptors are necessary in order for WIN-2 to induce
neurogenesis in the DG of the hippocampus of aged rats, as
determined by examination of DCX-immunoreactive cells in this
region. Blocking either CB1 or CB2 receptors was sufﬁcient to prevent
the increase in neurogenesis due to the WIN-2 treatment. Our results
using the TRPV1 receptor antagonist 5′-I-RTX are consistent with the
hypothesis that the CB1/2 agonist properties of WIN-2, and not its
antagonist actions at the TRPV1 receptor, were responsible for the
increase in neurogenesis. Therefore, the pharmacological action of
WIN-2 that underlies the increase in neurogenesis appears to be
unrelated to its ability to reduce microglia activation; blocking either
or bothof the CB receptors was insufﬁcient to prevent the reduction in
microglial activation by WIN-2 treatment but negatively affected
neurogenesis. Therefore, our results conﬁrm previous reports that
during developmental or pathological conditions (Aguado et al, 2005,
2007; Goncalves et al., 2008; Mulder et al., 2008) the endocannabi-
noid system regulates the proliferation and migration of newly
generated neurons. Moreover, our current results demonstrate that
both CB1 and CB2 receptors are required in an aged brain to restore
the proliferation of new neurons in the hippocampus.
Overall, the results of the current study are encouraging because
they identify a pharmacological approach targeting the CB and TRPV1
receptors that can produce short-term therapeutic beneﬁts on
cognitive function (Marchalant et al., 2008a), partially restore an
anti-inﬂammatory environment and stimulate neurogenesis in an
aged brain. This multi-target approach may prove to be neuroprotec-
tive against neurodegenerative processes associated with inﬂamma-
tion-related pathological aging as well as during normal aging.
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